Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Polymorphisms and GLP-1 RA Response in T2DM
NCT05037045Completed
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Jan 2019
- Primary completion
- Oct 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Glycated Hemoglobin at 6 months, Fasting Plasma Glucose at 6 months and 2 more. Started Jan 2019; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05037045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037045.